Manuela Maronati | SVP Global Asset Head, Neuroinflammation and Rare Diseases
UCB

Manuela Maronati is a seasoned leader in the pharmaceutical industry, currently serving as the Senior Vice President and Global Asset Head for Neuroinflammation and Rare Diseases at UCB. With a strong background in drug development and strategic planning, Manuela has a proven track record of driving innovation and delivering results in the healthcare sector. Manuela joined UCB in April 2022 with the mandate to build the European Rare Disease Organization in charge of launching new assets in Myasthenia Gravis and in TK2D in the European countries. Before joining UCB Manuela spent the last 12 years of her carrier in helping American biotech companies to build from scratch their European commercial footprints and successfully launch their rare or ultra-rare disease assets in Europe. Previously Manuela has covered different marketing and sales roles in Amgen, launching several oncology products, both at International and national level. She has also worked as an Engineer designing, building, and validating pharmaceutical biotech and fill-finishing plants. Manuela is a chartered Chemical Engineer with an MBA from Bocconi University. She has a passion for supporting Patient Organizations to develop their skills and advocate for better care and empower young generations and especially women to develop their full potential.